Correction: Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to continuous positive airway pressure therapy
Yu-Tong Hu, Yue-Nan Ni, Hugi Hilmisson, Robert Joseph Thomas
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVagus Nerve Stimulation Research · Respiratory Support and Mechanisms
The title of this article was erroneously given as: “Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to contimuous positive airway pressure therapy”. The correct title of the article is “Pathological respiratory chemoreflex activation predicts improvement of neurocognitive function in response to continuous positive airway pressure therapy.”
An extraneous period was present after the citation “(Lv et al., 2023).”
A correction has been made to the section Background, second paragraph:
“Continuous positive airway pressure (CPAP), which is regarded as the first line therapy for OSA, can improve hypoxia in OSA patients, reduce sleep fragmentation, and reverse sympathetic nerve excitation (Patil et al., 2019), but there is controversy regarding whether CPAP can improve cognitive dysfunction caused by OSA (Bucks et al., 2013). The existence of complex pathologies especially high loop gain maybe a reason for the failure due to impairment in both effectiveness and adherence (Ni and Thomas, 2023; Cheng et al., 2024). It is also plausible that pathological respiratory chemoreflex activation and the resulting heightened sympathetic activation and other pleotrophic effects such as oxidative stress, inflammatory response, and neuronal damage (Lv et al., 2023) may influence development of neurocognitive dysfunction, and response to treatment.”
The word “imfluences” was misspelled.
A correction has been made to the section Background, fourth paragraph:
“As described in our previous work, narrow band elevated low frequency coupling (e-LFCNB) measured by cardiopulmonary coupling sleep spectrograms is a biomarker indicating periodic breathing and central sleep apnea (Thomas et al., 2007), indicating high loop gain. Our previous study showed that e-LFCNB was a strong predictor for blood pressure dropping after CPAP in OSA (Ni et al., 2024). However, whether it influences neurocognitive function improvement by CPAP is not known.”
The original version of this article has been updated.